Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
暂无分享,去创建一个
Roman Rouzier | Etienne Rouleau | Nicolas Servant | Anne Vincent-Salomon | Xavier Paoletti | Olivier Delattre | Maud Kamal | A. Vincent-Salomon | O. Delattre | R. Rouzier | I. Bièche | X. Paoletti | N. Servant | Philippe Bédard | A. Tsimberidou | M. Kamal | E. Rouleau | G. Pierron | Ivan Bièche | Christophe Le Tourneau | Apostolia-Maria Tsimberidou | Gaëlle Pierron | C. Callens | Céline Callens | Philippe Bedard | M. Alt | Marie Alt | C. le Tourneau
[1] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[2] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Tatiana Popova,et al. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data , 2014, Bioinform..
[4] P. Gestraud,et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial , 2014, British Journal of Cancer.
[5] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[6] Amber M. Johnson,et al. A decision support framework for genomically informed investigational cancer therapy. , 2015, Journal of the National Cancer Institute.
[7] C. Cui,et al. Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma. , 2014, Chinese clinical oncology.
[8] H. Mudhar. Royal College of Pathologists , 1990, The Lancet.
[9] O. Delattre,et al. MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. , 2013, Cancer genetics.
[10] P. Pandolfi,et al. Haplo‐insufficiency: a driving force in cancer , 2011, The Journal of pathology.
[11] R. Schilsky,et al. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[13] Jill P. Mesirov,et al. Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.
[14] Jessica N Everett,et al. Traditional Roles in a Non-Traditional Setting: Genetic Counseling in Precision Oncology , 2014, Journal of Genetic Counseling.
[15] Thomas Bachelot,et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.
[16] Emmanuel Barillot,et al. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial , 2014, Front. Genet..
[17] Doris Berger,et al. International Cancer Genome Consortium , 2013, Im Focus Onkologie.
[18] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[19] J. Nunemacher,et al. Optimal management of giant cell arteritis and polymyalgia rheumatica , 2012, Therapeutics and clinical risk management.
[20] klaguia. International Network of Cancer Genome Projects , 2010 .
[21] Richard Simon,et al. Implementing personalized cancer genomics in clinical trials , 2013, Nature Reviews Drug Discovery.
[22] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[23] Etienne Rouleau,et al. Guidance for laboratories performing molecular pathology for cancer patients , 2014, Journal of Clinical Pathology.
[24] B. Tops,et al. Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe , 2014, Molecular oncology.
[25] F. Collins,et al. First FDA authorization for next-generation sequencer. , 2013, The New England journal of medicine.
[26] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[27] Razelle Kurzrock,et al. Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.
[28] S. Sleijfer,et al. The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] I. Bièche,et al. Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.
[30] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[31] J. Thiery,et al. Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.
[32] R. Mason,et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. , 2008, Cancer research.
[33] David C. Smith,et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Soria,et al. From theoretical synergy to clinical supra-additive toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[36] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[37] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[38] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[39] Mark Cobbold,et al. Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study , 2014, PLoS biology.
[40] J. Salk. Clonal evolution in cancer , 2010 .
[41] Jorge S Reis-Filho,et al. Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.
[42] C Sotiriou,et al. The AURORA initiative for metastatic breast cancer , 2014, British Journal of Cancer.
[43] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[44] Camile S. Farah,et al. Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation , 2014, Cancers.
[45] M. Pestrin,et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients , 2015, Molecular oncology.
[46] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[47] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[48] C. Ponting,et al. Sequencing depth and coverage: key considerations in genomic analyses , 2014, Nature Reviews Genetics.